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Abstract
Background: The clusterin (CLU) gene has been identified as an important risk locus for Alzheimer’s disease (AD).
Although the actual risk–increasing polymorphisms at this locus remain to be identified, we previously observed an
increased frequency of rare non-synonymous mutations and small insertion-deletions of CLU in AD patients, which
specifically clustered in the β-chain domain of CLU. Nonetheless the pathogenic nature of these variants remained
unclear.
Here we report a novel non-synonymous CLU mutation (p.I360N) in a Belgian Alzheimer patient and have explored
the pathogenic nature of this and 10 additional CLU mutations on protein localization and secretion in vitro using
immunocytochemistry, immunodetection and ELISAs.
Results: Three patient-specific CLU mutations in the β-chain (p.I303NfsX13, p.R338W and p.I360N) caused an alteration
of the subcellular CLU localization and diminished CLU transport through the secretory pathway, indicative of possible
degradation mechanisms. For these mutations, significantly reduced CLU intensity was observed in the Golgi while
almost all CLU protein was exclusively present in the endoplasmic reticulum. This was further confirmed by diminished
CLU secretion in HEK293T and HEK293 FLp-In cell lines.
Conclusions: Our data lend further support to the contribution of rare coding CLU mutations in the pathogenesis of
neurodegenerative diseases. Functional analyses suggest reduced secretion of the CLU protein as the mode of action
for three of the examined CLU mutations. One of those is a frameshift mutation leading to a loss of secreted protein,
and the other two mutations are amino acid substitutions in the disulfide bridge region, possibly interfering with
heterodimerization of the α- and β-chain of CLU.
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Background
Genome-wide association studies have provided compel-
ling evidence for a role of genetic variation in the clusterin
gene (CLU aka APOJ) in susceptibility of Alzheimer’s
disease (AD) [1, 2]. The strongest association was found
for the common single nucleotide polymorphism (SNP)
rs11136000 located in a non-coding, intronic CLU re-
gion. The causal variant explaining the association how-
ever remains to be identified.
We previously demonstrated that, independent of the
reported association signal, rare (minor allele frequency
< 1 %) non-synonymous and insertion/deletion muta-
tions in the CLU β–chain are associated with increased
AD risk [3]. Numerous of these rare mutations are pre-
dicted as pathogenic based on PolyPhen and SIFT,
which are programs considering evolutionary conserva-
tion, sequence-based and structure-based features [4, 5].
Nonetheless, interpreting the functional consequences of
CLU variants remains challenging given the plentitude of
biological functions in e.g. protein chaperoning, apoptosis,
and complement activation. Most interestingly, CLU is as-
sociated with AD-related pathways: as an Aβ chaperone
CLU can modulate both clearance and aggregation of Aβ,
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CLU acts as a lipid transporter in brain and it is involved
in neuronal apoptosis (reviewed in [6]). In brain, CLU is
predominantly secreted by astrocytes [7, 8].
The clusterin protein is synthesized as a 60–80 kD
precursor protein undergoing endoproteolysis resulting
in α and β chains which are joined together by disulfide
bonds. This glycosylated heterodimeric protein is consti-
tutively secreted. This secreted isoform (sCLU) results
from translation of the full clusterin mRNA that codes
for the 449 residues-long protein and contains a 22-mer
leader sequence. The sCLU is induced during stress and
inflammation and is believed to have cytoprotective and
chaperone functions [9]. It was shown that two differen-
tially processed CLU isoforms in brain (of 501 and of 449
amino acids respectively) both produce secreted proteins
[10]. In addition to sCLU forms, less abundant non-
secreted, intracellular CLU – cytoplasmic and trun-
cated nuclear – forms have been described. These
result from alternative splicing events leading to shorter
mRNA variants lacking exon 5 [11] or exon 2 [12]. Op-
posed to the protective effects of the extracellular sCLU
forms, the intracellular forms (iCLU) are linked to cell
cytotoxicity [13].
Interestingly the AD-associated non-synonymous mu-
tations and insertion/deletions in CLU were mainly
present in the β-chain domain, at the interface with
the α-chain, presuming a role for the β protein subunit
in disease [3]. We designed an assay for high-throughput
analysis of the CLU coding regions based on multi-
plex amplification of specific targets for resequencing
(MASTR™) and massive parallel sequencing. Here we
report the identification of a novel mutation (p.I360N) in
a Belgian Alzheimer patient. Moreover, we explored the
effect of this mutation, together with 10 previously re-
ported coding CLU mutations, on subcellular localization
and secretion of CLU protein. We found that multiple
CLU mutations led to reduced CLU secretion, as shown
by the higher retention in the endoplasmic reticulum (ER)
and concomitant decreased concentration in the Golgi ap-
paratus. These findings illustrate that rare Alzheimer mu-
tations in the CLU β-chain can deregulate normal CLU
secretion and lead to protein degradation in ER before
subsequent trafficking towards Golgi.
Results
Identification of a novel AD mutation in the β-chain domain
Mutation analysis of the CLU β-chain encoding exons in
74 Alzheimer patients identified a yet unreported (from
1000GP, EVS) missense mutation (p.I360N) in one pa-
tient with clinically probable late-onset AD (onset age
of 78 years), and two missense mutations previously
observed in patients and controls [3] (Table 1). The
p.I360N variant lies within the central cysteine-rich re-
gion adjacent to Cys354, Cys357 and Cys365 forming
disulfide bonds at the interface between the CLU β-
chain and α-chain. Three in silico prediction programs
suggested a damaging effect of this variant (Table 1).
Functional follow-up of small insertion/deletion and
missense mutations in CLU
The p.I360N mutation and nine previously reported
CLU variants [3] were selected for further functional in-
vestigation. This selection included disease-associated
CLU mutations with predicted pathogenic effects, a pre-
dicted benign variant (p.A309T) and two variants ob-
served in both patients and controls (p.P322L, p.N369H)
(Table 2). Of note, p.A309T and T445_D447del occur as
a double mutation in Belgian, but not in French or Can-
adian patients, hence these mutations were investigated
individually as well as in combination. In total, 11 differ-
ent constructs were generated.`
The CLU β-chain variants affect CLU localization in HeLa
cells
To investigate whether the AD-associated CLU mutations
affect the subcellular localization of CLU, we performed
Table 1 Rare non-synonymous CLU mutations identified in 74 AD patients
Gene
locationa
DNAb Proteinc Proteind dbSNP This
study
Previous
study [3]
Protein
location
PolyPhen2
(PSIC)
SIFT PMUT EVS (EA) 1000GP
Exon 6 c.1079 T > A p.I360N p.I308N − 1 AD - β-chain Possible
(0.677)
Not tolerated
(0.00)
Pathological
(0.9659)
- -
Exon 5 c.701G > A p.R234H p.R182H − 1 AD 2 AD, 1 C α-chain Probably
(0.995)
Tolerated
(0.15)
0.0002 0.001
Exon 5 c.764C > T p.T255I p.T203I rs4127629 1 AD 5 AD, 6 C β-chain Benign
(0.041)
Tolerated
(0.29)
Pathological
(0.6284)
0.003 0.001
Abbreviations: AD Alzheimer patient, C control individual, AAO Age of Onset, y years
aGene location position according to CLU transcript with 9 coding exons [NM_001831.2]
bNumbering according to CLU mRNA sequence starting at the A of the ATG translation initiation codon in [NM_001831.2]
cNumbering according to CLU protein sequence [NP_001822.2 consisting of 501 AA]
dFor easy comparison to Exome Variant Server, numbering according to updated CLU protein sequence [NP_001822.3 consisting of 449 AA] is given. Mutations
were compared to our findings previously described in Belgian patients [3]. Predictions of pathogenicity was performed using Polyphen2 (benign/possibly
damaging/probably damaging), SIFT (tolerated/not tolerated) and PMUT (neutral/pathological). Minor allele frequency (MAF) was compared to Exome Variant
Server (EVS) in European American individuals (EA) and 1000 GenomesProject (1000GP)
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live cell imaging and immunocytochemistry experiments
on HeLa cells transiently transfected with EGFP-tagged
wild-type (wt) and 11 mutated CLU constructs. Of all mu-
tants, 3 (p.R338W, p.I303NfsX13 and p.I360N) showed al-
tered CLU localization compared to wild-type CLU and
other variants (Fig. 1).
The CLU-EGFP signal of wild-type CLU-expressing
cells was predominantly present in distinct zones in the
cytoplasm close to the nucleus (Fig. 2a-b). This location
represents the Golgi apparatus, as established by the typ-
ical cisterna-shaped structures (Fig. 2b) and the perfect
overlap when co-staining with a Golgi marker (Giantin)
(Fig. 1b). CLU-EGFP could also be detected at lower in-
tensities in the endoplasmic reticulum (ER): ER mem-
brane structures could be clearly discerned, which also
colocalized with a marker for the ER (PDI) (Figs. 1a, 2c).
In addition, more intense EGFP signals were detected in
vesicular structures, reminiscent of endosomes (Fig. 2c).
No nuclear clusterin staining was detected, consistent
with the secreted CLU construct lacking the nuclear re-
tention signal (NM_001831.1) (Fig. 2b).
When examining the different CLU mutations for their
cellular distribution of CLU-EGFP, the high intensity sig-
nal accumulation in the Golgi was clearly lost for CLU
mutations p.I303NfsX13, p.R338W and p.I360N, when
compared to wild-type and all other CLU coding vari-
ants (Figs. 1 and 2d-f and Additional file 1: Figure S1,
Additional file 2: Figure S2 and Additional file 3: Figure S3).
To quantify this, we measured the relative amount of
CLU-EGFP signal in the Golgi region for the different
cell lines and found significantly reduced CLU-EGFP in-
tensity in Golgi for p.I303NfsX13, p.R338W and p.I360N
(Fig. 3a). For these three mutants, CLU-EGFP signal was
almost exclusively present in ER, which was verified by a
drastic increase of the colocalization measurement of
the CLU-EGFP signal with an ER marker (Fig. 3b).
For p.T345M, a decreased ER localization was ob-
served, albeit no change was observed for this variant in
Golgi. The altered ER signal is most likely due to the
large intra-variant variability (Fig. 3b).
Most conclusive effects were observed for p.I303NfsX13,
p.R338W and the novel mutation p.I360N. Mutant
p.I303NfsX13 results in a premature stop codon and is
predicted to be degraded by the cellular mRNA surveil-
lance machinery prior to processing through the secretory
pathway. This is confirmed by its increased ER levels and
protein absence in Golgi (Fig. 3).
The CLU β-chain variants alter CLU secretion in HEK293
cells
To further explore whether CLU β-chain mutations
interfere with normal CLU processing in isogenic cell
lines, cleaved secreted CLU (sCLU) and uncleaved full-
length CLU (FL-CLU) levels were measured in HEK Flp-
In cells stably transformed with plasmids encoding CLU
wild-type and mutations (Fig. 4). On western blot, over-
expression of CLU p.R338W and p.I360N resulted in de-
creased sCLU levels in cell medium (CM) and increased
amounts of FL CLU in cellular lysate (CL) relative to wt
CLU (Fig. 4a). ELISA measurements on HEK Flp-In cells
showed that for wt cells, 91 % of total CLU was secreted
by the cells while 9 % of total CLU was present in CL.
Compared to this ratio in wt cells, reduced ratios and
sCLU levels were detected for p.R338W cells (68/32
Table 2 Rare coding β-chain variants transfected in cells
# Gene locationa Proteinb Proteinc PolyPhen2 (PSIC) SIFT
Alzheimer specific CLU mutations
1 Exon 5 p.I303NfsX13 p.I251NfsX13 - -
2 Exon 5 p.A309T p.A257T Benign (0.32) Tolerated (0.65)
3 Exon 6 p.R338W p.R286W Probable (1.00) Not tolerated (0.00)
4 Exon 6 p.T345M p.T293M Probable (1.00) Tolerated (0.09)
5 Exon 6 p.I360N p.I308N Possible (0.68) Not tolerated (0.00)
6 Exon 7 p.E431Q p.E379Q Possible (0.83) Tolerated (0.35)
7 Exon 7 p.T440M p.T388M Possible (0.92) Not tolerated (0.01)
8 Exon 8 p.T445_D447del p.T393_D395del - -
CLU mutations observed in patients and controls
9 Exon 5 p.P322L p.P270L Benign (0.03) Tolerated (0.25)
10 Exon 7 p.N369H p.N317H Probable (1.0) Tolerated (0.15)
aGene location position according to CLU transcript with 9 coding exons [NM_001831.2]
bNumbering according to CLU protein sequence [NP_001822.2]
cFor easy comparison to variants reported in Exome Variant Server (EVS), numbering according to recently updated CLU protein sequence [NP_001822.3
consisting of 449 AA] is given. The first 8 mutations were observed in AD patients only, variants 9 and 10 in patients and controls from this and previous study [3]
Belgian carriers of p.T445_D447del also harbor p.A309T. Predictions of pathogenicity of missense mutations was performed using Polyphen2 (benign/possibly
damaging/probably damaging) and SIFT (tolerated/not tolerated). Small indels and non-synonymous mutations with predicted pathogenic effects are marked
in bold
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ratio (95 % C.I. 0.11-0.28); p < 1×10−4) and p.I360N cells
(15/85 ratio (95 % C.I. 0.01-0.03); p < 1×10−4), indicating
CLU is retained intracellularly (Fig. 4b). These results
were in line with quantification of the western blot bands
(Fig. 4c). Identical findings were observed in HEK293T
cells where p.R338W and p.I360N showed reduced sCLU
in CM versus FL-CLU in CL (p.R338W: 52.8/47.2 ratio
(95 % C.I. 0.15-0.31), p < 1×10−5; p.I360N: 12.3/87.7 ratio
(95 % C.I. 0.02-0.05), p < 1×10−5) compared to wt (76.6/
23.4 ratio) (Additional file 4: Figure S4).
Since antibodies against the β-chain were used, no
protein levels could be measured for HEK-Flp In and
Fig. 1 Localization of CLU-EGFP for different CLU coding mutations. Immunocytochemistry of CLU with markers for Golgi or ER was performed
on HeLa cells transiently overexpressing wild-type CLU-EGFP or variants p.I303NfsX13, p.R338W, p.T345M, p.I360N and p.N369H. a The localization
of CLU in ER is altered for p.I303NfsX13, p.R338W and p.I360N, compared to wt, p.T345M and p.N369H. b The CLU localization tends to concentrate in
Golgi for wt and most missense mutations, (p.T345M and p.N369H are shown as example) while mutations p.I360N, p.I303NfsX13 and p.R338W showed
decreased EGFP signal in the Golgi. Merged images for CLU (EGFP, green), ER (PDI, red) or Golgi (Giantin, red), nucleus (DAPI, blue), and actin
cytoskeleton (Phalloidin, grey). The scale bar represents 25 μm
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HEK293T cells transduced with p.I303NfsX13 lacking
the β-chain. None of the other mutations showed the
pattern of intracellular CLU retention observed for
p.R338W and p.I360N. Of note, however, the sCLU iso-
form of p.T345M consistently showed lower molecular
weight (~30 kDa) (Fig. 4a, Additional file 4: Figure S4a).
Discussion
The CLU gene has been identified as an important novel
risk locus for Alzheimer’s disease [1, 2, 14]. After BIN1
and PICALM, the genome-wide significance level of
CLU (overall p = 2.8×10−25) ranks third on the list of the
largest AD meta-analysis combining genetic information
of 74,046 individuals [14]. As an extracellular chaperone,
clusterin interacts with Aβ1–40 oligomers and is able to
influence both its aggregation and disaggregation by se-
questration in AD [15].
We previously hypothesized that not only common
CLU variants, but rare non-synonymous and small inser-
tion/deletion mutations play a role in AD [3]. The dis-
covery of multiple patient related CLU mutations in
Belgian, French and Canadian individuals and a significant
meta-analysis for rare variants in the β-chain were in favor
of this hypothesis. More specifically, we found that rare
coding mutations (missense and small insertion-deletions)
in the CLU β-chain were associated with AD risk.
Here we explored the possible effect of these CLU mu-
tations, including a novel mutation in the β-chain, on
subcellular localization and secretion. As observed in
wild-type cells, CLU is a secreted protein that is local-
ized to Golgi and to lesser extent to endoplasmic
reticulum, both compartments of the classical secretory
pathway. Of interest, our findings suggest that Alzheimer-
related mutations located at the cystein-rich region of the
CLU β-chain (i.e. p.R338W and p.I360N) deregulate nor-
mal CLU secretion and lead to protein retention and deg-
radation in ER before subsequent trafficking towards
Golgi. This was shown by the increased CLU intensity in
ER and concomitant decreased Golgi signal. The same
holds true for p.I303NfsX13 for which almost complete
ER retention was observed, an expected finding since this
variant was predicted to result in a truncated protein.
Compared to wild-type cells, the ratio between CLU se-
cretion in cell medium and uncleaved full-length CLU in
Fig. 2 Localization of CLU-EGFP in HeLa cells. The distribution of CLU–EGFP wild-type (a-c) and one of the CLU coding mutations p.R338W (d-f) is
shown for the entire cell (a and d), and for enlarged regions in the perinuclear region (b and e) and the cell periphery (c and f) of the same cell.
For wild-type CLU the most intense EGFP signal was present in the Golgi (a and b) and in vesicles in the cytoplasm (a and c) in addition to the
ER, whereas for p.R338W the CLU EGFP seemed almost exclusively present in the ER (d-f). No CLU-EGFP was present in the nucleus (b and e). The
scale bar represents 5 μm
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Fig. 3 Quantifications of CLU-EGFP intensity in ER and Golgi of HeLa cells expressing CLU mutations. a For Golgi the ratio of the mean CLU-EGFP
intensity inside versus outside the Golgi region was determined after excluding cells with low EGFP signal outside Golgi. b For ER, the Pearson’s
correlation coefficient between the fluorescence channels of CLU-EGFP and PDI is represented. Measurements were performed on individual cells
with ImageJ. Data are represented as median values, with lower and upper quartiles and the value ranges (whiskers) with a minimum of 20 cells
per CLU variant. (*p < 0.05; **p < 0.01 after Bonferroni correction)
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cell lysate was significantly altered for mutations p.R338W
and p.I360N. Of six mutation carriers for whom serum
CLU levels could be determined, one patient carrying
p.R338W and the p.I360N carrier showed decreased CLU
levels in serum compared to average serum CLU in AD
patients without CLU mutations (n = 314) as well as con-
trol individuals (n = 349). Their levels were within or just
below the interquartile range of values observed in the full
AD cohort (Additional file 5: Figure S5). Because of small
numbers and impossibility to adequately control for
stressors that may induce sCLU in vivo these observations
should be interpreted with caution.
The pattern of ER retention was observed for 3 out of
10 mutations. The other 7 mutations include two variants
observed in both patients and control individuals (p.P322L
and p.N369H), a predicted benign variant (p.A309T) and a
Fig. 4 Visualization and quantification of CLU secretion for different CLU coding mutations in HEK Flp-In cells. a Immunoblot visualization of CLU
Flp-In cells, showing lower sCLU levels in cell media (CM) and increased expression of full length (FL) CLU in cellular lysates (CL) for p.R338W and
p.I360N. Alpha-tubulin staining is incorporated as an equal loading control. b ELISA quantification of CLU in HEK Flp-In CM and CL, presented as
relative proportions of total CLU in CM and CL, displays a significant ratio decrease for p.R338W and p.I360N (*p < 1×10−4). N corresponds to the
number of independent experiments. c Quantification of western blot band intensities in CM and CL of HEK Flp-In cells, presented as relative
proportions of total CLU in CM and CL, with a significantly decreased CLU ratio of CM/CL for p.R338W and p.I360N (*p < 1×10−4). N corresponds
to the number of independent experiments. d Western blot CLU intensities in CM (blue) and CL (red) normalized against α-tubulin and logarithmically
rescaled against wt. a-d Mutant p.I303NfsX13 was not included in these experiments because lack of the ß-chain interferes with antibody binding
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variant predicted only possibly pathogenic by one in silico
prediction program (p.E431Q). No effects on CLU locali-
zation and secretion were observed for the 3-amino acid
deletion, and p.T440M and p.T345M despite being pre-
dicted pathogenic. Conceivably, these mutations may in-
fluence other CLU functions, such as altered binding to
amyloid particles, disturbed microglia receptor binding
or disturbed binding of other CLU ligands. Both the 3-
amino acid deletion and p.T440M are located outside
the disulfide bond region, while p.T345M is located in
this region. Of note, secreted CLU of the p.T345M mu-
tant consistently had lower molecular weight (~30 kDa)
on western blots, likely reflecting the absence of a pos-
sible phosphorylation site, but this needs further
exploration.
Both our western blot and ELISA data confirmed re-
duced CLU secretion for p.I303NfsX13, p.R338W and
p.I360N through the secretory pathway and suggest a
potential mechanism for pathogenicity of these muta-
tions. Altered cellular localization and in turn reduced
secretion to the extracellular space are indicative of im-
proper folding or mis-assembly of the clusterin subunits,
suggesting that these observed β-chain mutations interfere
with the biosynthetic-secretory CLU pathway. In these pa-
tients, the reduced CLU secretory levels throughout life
may hamper CLU upregulation and elevation which is
noted in the process of AD [16].
An extension of our finding that AD risk is increased
with CLU mutations that decrease CLU secretion is that
other factors reducing CLU secretion may increase risk
as well. This is in line with the observation that SNP
rs11136000 was associated with increased CLU expres-
sion, which in turn may act in reducing AD risk [10].
Moreover, higher clusterin concentrations in plasma
have been associated with slower rates of brain atrophy
in mild cognitive (MCI) patients [17].
The use of a cell over-expression system is unlikely to
have biased our findings since consistent secretory
localization patterns for intact full length CLU were ob-
served. Furthermore, CLU-p.insA cells express truncated
CLU which leads to a distorted localization pattern that
is consistent with protein degradation. Therefore our
assay was suitable for observing the effect of high impact
mutations. While strongest CLU expression is found in
brain astrocytes, the stretched phenotype of HeLa cells
allows accurate cytoplasm localization, and isogenic Flp-
In cells have constant protein expression, making these
cell types most suitable in first-line characterization of
mutations interfering with CLU localization and secre-
tion. Moreover previous studies have shown that stable
transfected HEK293 cells produced similar CLU protein
as human plasma protein in terms of glycosylation, pro-
teolytical cleavage into α and β-subunits and chaperone
activities [18].
A limitation of the present study is that only the
secretory CLU isoform has been investigated, selected
because of its predominance in brain and chaperone ac-
tivities towards Aβ and role in lipid metabolism in AD.
A recent study exploring the role of intracellular CLU
(iCLU) in AD, reported an interaction between iCLU
and tau and BIN1 protein [19]. No interaction was de-
tected between BIN1.1 and iCLU for p.I303NfsX13 (de-
noted as MT8 in [19]), providing evidence that the
CLU-BIN1 interaction occurs through their coiled-coil
motifs [19]. Interestingly, an increased generation of
iCLU (50 kDa) relative to sCLU (37 kDA) was found for
p.R338W (MT1 in [19]), which is in line with our obser-
vation of decreased p.R338W secretion relative to full-
length CLU in vitro. Following transfection of the
secreted CLU isoform, we did not observe the intracellular
CLU isoform but the finding that full length CLU is ele-
vated for p.R338W and p.I303NfsX13 shows that these
mutations are implicated in disease etiology. Mutations
that diminish CLU secretion may potentially modify AD
risk by hampering CLU upregulation and protective
mechanisms during stress and inflammation (e.g. amyloid
clearance). Alternatively, the combination of reduced CLU
protection and increased CLU cytotoxicity may be in-
volved in lowering the threshold of disease onset.
Conclusions
Identification of rare mutations in Alzheimer risk genes
may provide additional insights in the molecular mecha-
nisms underlying a genetic association. Moreover, the
ability to functionally characterize the effect of rare vari-
ants will become increasingly pressing in the era of
massive parallel re-sequencing. The data presented here
lend further support to the contribution of rare coding
CLU mutations in the pathogenesis of Alzheimer’s disease,
and suggest reduction of secreted CLU as a possible dis-
ease mechanism, specifically for a frameshift mutation and
two mutations altering the disulfide bridge region of the
protein. The mode of action of the other predicted patho-
genic mutations warrants further investigation.
Methods
Population descriptives
Since publication of our previous data [3], 74 additional
Alzheimer patients (mean age of onset 82 ± 11.3 years,
%female 56.3) were screened for CLU coding exons. Pa-
tients were ascertained at the Memory Clinic of the
ZNA Middelheim and Hoge Beuken, Antwerp, Belgium
(S.E.,P.P.D.D.) in the frame of a prospective study of
neurodegenerative and vascular dementia in Flanders,
the Dutch-speaking region of Belgium [20, 21], and at
the Memory Clinic of the University Hospitals of Leuven
(UHL), Gasthuisberg, Leuven, Belgium (M.V.,R.V.) as
part of a prospective study on the molecular genetics of
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cognitive impairment using the same clinical assess-
ments and biosampling schemes. Each patient under-
went a neuropsychological examination and structural
and/or functional neuroimaging [22].
Genetic screening
We designed a PCR-based target enrichment assay using
MASTR™ technology (Multiplicom, Niel, Belgium) in-
cluding fourteen CLU fragments (3.3 kb) covering the 9
CLU coding exons, flanking intron-exon boundaries and
UTR regions (NM_001831.2 and NM_20339.1). Primers
for multiplex PCR were designed using mPCR. Multiplex
PCR was performed for amplification of the target re-
gion, followed by purification of the pooled amplicon
library using Agencourt AMPureXP beads (Beckman
Coulter, CA, USA). Patient-specific barcodes (Multipli-
com, Niel, Belgium) were incorporated during a univer-
sal PCR step. Barcoded samples were pooled prior to
bridge amplification and sequencing on MiSeq, using
the reagent kit v2, generating 250 bp paired-end reads
(Illumina, San Diego, CA, USA). Data was processed
with the Illumina pipeline and Genomecomb’s [23] data
annotation and filtering package, including read align-
ment against build GRCh37/hg19 and mapping steps
with Burrows-Wheeler Aligner (BWA) [24] and variant
calling with Genome Analysis Toolkit (GATK) [25]. Rare
CLU variants were filtered on impact (frameshift, non-
sense, non-synonymous and splice variants), low-frequency
in 1000 Genomes Project [26] (frequency <0.01) and
European American samples of the NHLBI GO Exome
Sequencing Project (ESP6500 data set) (frequency <0.01).
Filtered variants were visually inspected using interactive
genomics viewer (IGV). In total, 78.5 % of the target re-
gion had a coverage ≥ 50x in all samples. Rare CLU vari-
ants were validated using Sanger sequencing as described
before [3]. The effects of non-synonymous substitutions
on protein function were evaluated with PolyPhen2 [5],
Pmut [27] and SIFT [4] programs.
cDNA constructs
The effect of CLU mutations on CLU secretion was mod-
eled using a synthetic cDNA construct of NM001831.3
(GeneCopoeia), starting from the second ATG codon for
exclusive expression of the short secreted isoform (449
AA) [10]. Using attB sites containing primers, CLU ORF
was amplified and subsequently recombined into the
pDONR221 vector using the Gateway Cloning System
(Life Technologies). In total, 11 CLU missense and small
insertion-deletion mutations were introduced in this
pDONR construct by site-directed mutagenesis using
Kapa High Fidelity Polymerase. All sequences were verified
using Sanger sequencing and subsequently transferred to
pEGFPC-GW, an in-house designed gateway-compatible
destination vector with C-terminal EGFP tag (without
stopcodon), to allow the expression of CLU-EGFP fusion
proteins.
In addition, the ORFs from wild-type and CLU mutants
(with stop codon) were cloned into the pEF/FRT/V5 Gate-
way vector (Life Technologies) and the pLENTI6/V5 vec-
tor (Life Technologies) to generate stable CLU expressing
cell lines by Flp recombinase-mediated integration, or by
lentiviral vector transduction, respectively.
Cell culture
HeLa cells (Henrietta Lack cells, cervical cancer cells;
ATCC) were maintained in Minimal Essential Medium
(MEM) supplemented with 10 % (v/v) fetal bovine serum,
100 U/ml penicillin/streptomycin at 37 °C in a humidified
5 % CO2 atmosphere.
Flp-In HEK293 cells (Life technologies), stable Flp-In
cell lines and transduced HEK293T cells expressing the
CLU gene were cultured in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with Zeocin (400 μg/ml,
Life Technologies, HygromycinB (200 μg/ml, Ducheva Bio-
chemie) or Blasticidin (4 μg/ml, Invivogen) respectively.
Lentiviral vector production
Human immunodeficiency virus type 1 (HIV-1)-derived
lentiviral vectors were produced by a standardized
three plasmid transient transfection protocol [28]. Briefly,
HEK293T cells were transfected with a second-generation
packaging plasmid pCMV dR8.91, an envelope plasmid
encoding the VSV-G protein, and the pLenti6/V5 transfer
plasmid carrying the CLU CDS with mutations of interest
using calcium phosphate as transfection reagent. The cell
supernatant containing the lentiviral particles was har-
vested 48 h post-transfection, filtered using a 0.45 μm
PVDF membrane (Millex), aliquoted and stored at −20 °C.
The total amount of LV was determined by measuring the
lentivirus associated p24 antigen content using a commer-
cial enzyme linked immunosorbent assay (HIV-1 p24
ELISA, Cell Biolabs).
Transfections and lentiviral transductions
Nearly confluent HeLa cells were transfected in 35 mm
dishes with plasmids encoding the wild-type and mu-
tant CLU-EGFP fusion protein using Lipofectamine
2000 (Life Technologies) according to the manufac-
turer’s recommendations.
Secondly, to generate stable CLU overexpressing HEK
Flp-In cell lines, 1.2×106 cells per 100 mm plate were
co-transfected with a total of 10 μg DNA of the pEF/
FRT/V5 and pOG44 plasmids at a 1/9 ratio, using Lipo-
fectamine 2000 (Life technologies). Cells were selected
with HygromycinB antibiotic after 48 h. Integration of
the CLU wild-type and mutant cDNA was sequence-
verified on gDNA isolated from these cells (DNA blood
minikit, Qiagen).
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Thirdly, HEK293T cells (HCL4517, Fermentas) were
transduced for 24 h with various LV vectors normalized
to P24 antigen (infectious titer of 2.107 TU). Selection in
DMEM media containing Blasticidin resulted in stable
polyclonal CLU expressing HEK293T cell lines.
Live cell imaging and immunocytochemistry on HeLa cells
Examination of living (unfixed) HeLa cells was per-
formed 48 h after transfection with CLU-EGFP express-
ing constructs. Cells grown on glass bottom imaging
dishes (MatTek Corporation) were imaged on a Zeiss
LSM 700 confocal microscope equipped with a stage top
incubator (Pecon Gmbh), maintaining conditions of 37 °C
and 5 % CO2.
For immunocytochemical staining, HeLa cells grown
on glass coverslips were fixed in 3 % paraformaldehyde
(PFA) at 48 h after transfection with the CLU-EGFP
constructs. After washing with PBS and blocking for 1 h
with Donkey Serum (1:500, Abcam, Cambridge) at 37 °
C in PBT (PBS + 0.02 % Triton-X-100, 0.5 % BSA), cells
were incubated for 1 h at room temperature with goat
anti-EGFP antibody (1:2000, Abcam, Cambridge) together
with a marker for either Golgi (rabbit anti-giantin, 1:1000,
Covance, Rotterdam, The Netherlands) or ER (mouse
anti-PDI, 1:100, Abcam, Cambridge). Subsequently, sec-
ondary antibody incubation for 1 h at room temperature
(Donkey anti-Rabbit Alexa Fluor 594 and Donkey anti-
Goat, both at 1:500, Life Technologies), F-actin cyto-
skeleton staining (Phalloidin conjugated to Alexa Fluor
647 (25 min, 1:30, Life Technologies) and nuclear DAPI
staining (4’, 6-diamidino-2-phenylindol, 100 ng/ml,
10 min, Bio-Rad, Nazareth Eke, Belgium) was per-
formed with intermittent washes in PBT. After a final
wash step with PBS, sections were mounted using
DAKO fluorescent mounting medium and stored at 4 °
C in the dark before being subjected to fluorescence
microscopy.
Image acquisition and quantification
Confocal images used for quantification (1892×1892,
106×106 nm2 pixels) were acquired on a Zeiss LSM 700
microscope with Zen 2009 software (Zeiss, Zaventem,
Belgium), using a EC Plan-Neofluar 40x /1.30 Oil object-
ive, while keeping identical acquisition settings (laser in-
tensities, detector gain, channel settings). Images of
EGFP-CLU and the organelle markers (ER or Golgi)
were acquired in different tracks (serial frame scanning)
to avoid any possible crosstalk between the channels.
Images were acquired and quantified with genotype la-
bels blinded for the investigators.
ImageJ [29] was used to measure both the relative
EGFP intensity in the Golgi and the colocalization with
the ER. In both cases the F-actin cytoskeleton staining
was first used to manually delineate the regions of the
cells, which were stored in ImageJ ROI manager files.
For quantification of the relative EGFP signal in the
Golgi, the Golgi region was segmented by using an auto-
matic threshold followed by filtering of the binary mask.
The ratio of mean EGFP intensity in and outside the
Golgi was calculated, corrected for the background sig-
nal, and based upon the mean intensity in the Golgi and
the mean intensity outside Golgi in the remaining cell
region. A fixed cutoff threshold of EGFP mean intensity
outside the Golgi region was used to exclude cells with
low EGFP signal. A minimum of 20 cells per genotype
were used to perform quantification. To quantify EGFP
colocalization with PDI, the ImageJ Coloc2 plugin was
used to measure the Pearson’s correlation coefficient be-
tween the two fluorescent channels in individual cells. For
both types of measurements (ER and Golgi), ImageJ
scripts (macro) were written and used to process and
analyze all images (and all genotypes) in batch.
Protein extraction
Both HEK Flp-In and HEK293T cells were grown to
confluence in a 100 mm dish format. After washing with
Dulbecco’s Phosphate-buffered saline (PBS), cell medium
was replaced by serum-free OPTIMEM I medium (Life
Technologies). Cell media and cell lysates were harvested
24 h later. One ml of cell medium, supplemented with the
protease inhibitor AEBSF (1 mM final, Calbiochem), was
centrifugated (15.000 g for 5 min, 4 °C). Supernatants
were aliquoted and immediately stored at −80 °C. After an
initial wash with PBS, cell lysates were prepared by col-
lecting the cells with a cell scraper followed by lysis with
2 ml NP40 buffer (Life Technologies) supplemented with
the protease inhibitor AEBSF. The cell lysates were incu-
bated on ice for 10 min, centrifugated (15.000 g for 5 min,
4 °C) and immediately stored at −80 °C.
CLU ELISA
Secreted CLU from conditioned medium and CLU from
cell lysates of HEK293T cells was quantified by a commer-
cial CLU ELISA (Human Clusterin Elisa RD194034200R,
Biovendor, Germany). All undiluted samples were run in
duplicate. Besides the quality control samples provided by
the manufacturer, inter-assay samples were run in each
experiment. Three independent experiments were per-
formed per mutation. Normalization was performed using
TGF-ß1. Because of a slight immunoreactive response of
the sample matrix, as observed in measurement of non-
transfected cells, the average of the immunoreactive re-
sponse was computed across three experiments and
subtracted from the observed data for each mutation.
Western blot and immunodetection
Protein concentrations were determined with a bicinch-
oninic acid colorimetric assay (BCA) (ThermoScientific).
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Equal amounts of protein (20 μg) were loaded and sepa-
rated on NuPAGE® 10 % Bis-Tris gels (Life Technologies).
Proteins were transferred onto polyvinylidene difluoride
membranes (Hybond P, Amersham Biosciences). After
blotting, membranes were blocked in 5 % skimmed milk
in PBS containing 0.1 % Tween® 20 (Merck) (PBT) for 2 h
at room temperature and probed overnight with a mouse
anti-clusterin antibody (1:200, B-5 Santa Cruz recognizing
the CLU β–chain) at 4 °C. Equal loading was controlled
using a mouse α-tubulin antibody (1:10000, GeneTex).
Immunodetection was achieved with horseradish peroxid-
ase (HRP)-conjugated sheep anti-mouse antibody (1:10000,
BioSciences) and an ECL Plus™ chemiluminescent detec-
tion system (GE Healthcare). Bands were visualized and
quantified using ImageQuant LAS 4000 equipment (GE
Healthcare Life Sciences).
Statistical analysis
For quantification of the colocalization experiments,
Pearson’s R correlation value was determined between
ER and CLU reactivity (using ImageJ Coloc2 plugin). For
Golgi measurements, ratios of mean intensity inside
Golgi versus outside Golgi apparatus were determined.
Means of the independent measurements were compared
to wt using ANOVA (Tukey HSD test). Extreme outliers
(n = 23 from 568 measurements), defined as values with
more than 3 standard deviations from the mean were re-
moved from the analysis.
For quantification of western blot data, CLU protein
levels in cell media and lysates were evaluated through
quantification of band intensities with ImageQuant soft-
ware (GE Healthcare Life Sciences). Independent mea-
sures of CLU intensity ratios between cell lysates and cell
media were used for further analysis. Cochran-Mantel-
Haenszel test was used to compare ratios of CLU in cell
medium versus lysate between CLU wt and mutant geno-
types. Bonferroni correction for 11 different constructs is
applied. P-values <0.0045 are considered significant. Re-
sults are represented as mean ratios of CLU in cell
medium and lysate (Fig. 4, Additional file 4: Figure S4).
Consent
All participants and/or legal guardians gave written in-
formed consent for participation in genetic studies, and
for publication of study results, in an anonymized man-
ner. Clinical study protocol and informed consent forms
for ascertainment were approved by the Ethics Commit-
tee of the respective hospitals at the sampling sites. Gen-
etic study protocols and informed consent forms were
approved by the Ethics Committees of the University of
Antwerp and the University Hospital of Antwerp,
Belgium.
Additional files
Additional file 1: Figure S1. The distribution of CLU-EGFP wt (top) and
CLU mt p.I360N (bottom) in Golgi and ER. CLU localization is shown for
the entire cell and for enlarged regions in the perinuclear region and the
cell periphery of the same cell. For wild-type CLU the most intense EGFP
signal was present in the Golgi, and in vesicles in the cytoplasm in
addition to the ER. For p.I360N, CLU EGFP seemed almost exclusively
present in the ER. No CLU-EGFP was present in the nucleus.
Additional file 2: Figure S2. The distribution of CLU-EGFP wt and CLU
mutations in relation to the ER. Localization of CLU (EGFP) and the ER
(PDI marker) is shown for a 21 μm× 21 μm region containing the
perinuclear zone of cells expressing the different CLU genotypes. For
p.I303NfsX13, p.R338W and p.I360N CLU EGFP is almost exclusively
present in ER, while for wild-type and the other mutations the most
intense signal is present in Golgi-resembling structures. Scale bar = 5 μm.
Additional file 3: Figure S3. The distribution of CLU-EGFP wt and CLU
mutations in relation to the Golgi. Localization of CLU (EGFP) and the
Golgi (Giantin marker) is shown for a 21 μm× 21 μm region containing
the perinuclear zone of cells expressing the different CLU genotypes. The
most intense CLU signal is present in Golgi, except for p.I303NfsX13,
p.R338W and p.I360N, which contain little CLU in the Golgi. Scale bar = 5 μm.
Additional file 4: Figure S4. CLU secretion is altered for CLU coding
variants in HEK293T cells. (a) Variants p.R338W and p.I360N showed
reduced expression in CM and increased expression in CL in HEK293T
cells. Α-tubulin staining is incorporated as an equal loading control (b)
Immunoblot quantification of the CLU ratio of CM/CL for different CLU
overexpressing HEK293T cell lines revealed alterations for p.R338W and
p.I360N compared to wt CLU (**p < 1×10−5).
Additional file 5: Figure S5. Serum CLU levels of CLU mutation
carriers. Log10-transformed circulating levels of CLU in serum of six
mutation carriers determined by ELISA. For p.R338W and p.T445_D445del,
serum CLU levels were determined in two carriers. For these mutations,
the diamond indicates the average of two carriers, and caps on bars
indicate the individual levels per carrier. The blue dashed line represents
the mean log transformed CLU serum concentration in 314 AD patients
(1.93 μg/ml). The blue dotted lines indicate lower and upper boundary of
the 95 % confidence interval (CI) of the mean (1.913 – 1.949 μg/ml). The
red dotted lines indicate the interquartile range (IQR 1.822 – 2.053 μg/ml).
Values for control individuals (n = 349; not shown in the figure): mean
1.931 μg/ml, 95 % CI 1.914 – 1.947 μg/ml), IQR 1.821 – 2.036 μg/ml).
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